Table 2.
Outcomes related with cost
|
Control n = 46 n (%) |
FG n = 46 n (%) |
Topical TXA n = 42 n (%) |
P | |
|---|---|---|---|---|
| Hospital stays (mean days, SD) | 11.3 (12.7) | 11.3 (6.1) | 11.6 (9.3) | 0.987 |
| Medical Complications | ||||
| Patients transfused | 20 (43.5) | 21 (45.7) | 14 (33.3) | > 0.461 |
| Number of red blood transfusions | 37 | 44 | 25 | 0.272 |
| Wound infection | 3 (6.5) | 0 | 2 (4.8) | 0.076 |
| Urinary tract infection/UAR | 2 (4.3) | 6 (13.0) | 1 (2.4) | 0.100 |
| Cardiac or respiratory failure/ Respiratory Infection | 1 (2.2) | 2 (4.3) | 0 | 0.387 |
| Prosthesis complications | 3 (6.5) | 3 (6.5) | 0 | 0.238 |
| Surgical reintervention | 4 (8.7) | 2 (4.3) | 5 (11.9) | 0.467 |
| Hematoma | 3 (6.5) | 7 (15.2) | 2 (4.8) | 0.381 |
| Mortality | 8 (17.4) | 1 (2.2) | 1 (2.4) | 0.007 |
TXA Tranexamic Acid, FG Fibrin Glue